An Open-label, Prospective, Multicenter Study to Investigate the Specificity of in Vivo Antibody Binding to Red Blood Cells in Subjects With Chronic Immune Thrombocytopenic Purpura (ITP) Treated With IgPro10 (Privigen) Who Have Shown Signs of Hemolysis

Trial Profile

An Open-label, Prospective, Multicenter Study to Investigate the Specificity of in Vivo Antibody Binding to Red Blood Cells in Subjects With Chronic Immune Thrombocytopenic Purpura (ITP) Treated With IgPro10 (Privigen) Who Have Shown Signs of Hemolysis

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 11 Dec 2017

At a glance

  • Drugs Immune globulin (Primary)
  • Indications Idiopathic thrombocytopenic purpura
  • Focus Adverse reactions
  • Sponsors CSL Behring
  • Most Recent Events

    • 11 Dec 2017 New trial record
    • 01 Nov 2017 Results published in the Transfusion Journal.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top